Friday, October 14, 2011
Telik Inc., of Palo Alto, Calif., initiated a Phase IIb trial evaluating Telintra (ezatiostat HCl) in patients with low to intermediate-1 IPSS risk, transfusion-dependent, nondeletion myelodysplastic syndrome, who have not been treated with hypomethylating agents such as Vidaza or Dacogen.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.